Analysts have lowered their price target for agilon health to $1.01 from $1.23. This reflects a more cautious outlook based on adjustments to expected revenue growth and a modestly higher discount rate, despite slight improvement in profit margin estimates.
What's in the News
- agilon health received a notice from the New York Stock Exchange (NYSE) regarding non-compliance with listing standards because the average closing price of its common stock was below $1.00 per share over a consecutive 30 trading-day period that ended November 4, 2025 (Key Developments).
- The NYSE notice does not immediately impact agilon health's stock listing. The company will remain listed and traded during a cure period as long as it continues to meet other listing requirements (Key Developments).
- To address non-compliance, agilon health plans to pursue a reverse stock split, pending approval by stockholders at the 2026 annual general meeting (Key Developments).
- agilon health has re-established earnings guidance for the fiscal year ending December 31, 2025, projecting total revenues between $5,810 million and $5,830 million (Key Developments).
Valuation Changes
- Consensus Analyst Price Target: Decreased from $1.23 to $1.01. This suggests a lower fair value estimate.
- Discount Rate: Increased slightly from 6.78% to 6.96%, which reflects higher perceived risk.
- Revenue Growth: Lowered from 7.54% to 7.25%. This shows a more conservative outlook.
- Net Profit Margin: Improved modestly from 5.32% to 5.48%.
- Future P/E: Decreased notably from 1.62x to 1.31x. This suggests lower expected earnings multiples.
Have other thoughts on agilon health?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.